Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06231641
Other study ID # DVG-IIS-M001-1008
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 11, 2024
Est. completion date September 1, 2025

Study information

Verified date January 2024
Source Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Contact Alex Desautels, M.D., Ph.D.
Phone 514-338-2692
Email alex.desautels@umontreal.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aim to evaluate whether a dose of 5 mg of lemborexant, as compared to a placebo, may improve daytime recovery sleep, without producing lingering sleepiness during wakefulness, using a 3-day simulated night shift protocol in the lab under constant monitoring.


Description:

After being informed about the study and potential risks, all patients giving written informed conset will undergo 2 screening visits to determine eligibility for study entry. Selected participants will then stay twice in the lab (active treatment condition and placebo condition), each visit lasting approximately 4 days. Participants will stay awake across the night and sleep during the day. Only the experimental condition will be different between the two visits (lemborexant or placebo). These experimental visits will be double-blind, in counterbalanced order and separated by an interval of at least 2 weeks (washout period).


Recruitment information / eligibility

Status Recruiting
Enrollment 24
Est. completion date September 1, 2025
Est. primary completion date September 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: Participants must fulfill all of the following inclusion criteria to be eligible for inclusion in this study: 1. Men or women aged between 30 and 60 years, inclusive 2. Be willing and able to give informed consent for study participation 3. Participants must not have done shiftwork in the past year 4. Normal vital signs values are: oral body temperature between 36.1 and 37.5 ºC (95 and 99.5 °F), supine SBP between 90 and 140 mmHg inclusive; supine DBP between 55 and 90 mmHg inclusive; heart rate between 50 and 100 bpm inclusive. 5. Be willing to comply with all study requirements and procedures for the duration of the study, including refraining from consuming alcohol 48 hours prior to each experimental visit and grapefruit products (juice or fruit itself), Seville orange, lime, pomelo, carambola and pomegranate during all the duration of the study (from Visit 1 to Visit 4). 6. Women who: - Are postmenopausal, with amenorrhea for at least 1 year before the screening visit, OR - Are surgically sterile, OR - If of childbearing potential agree to practice effective double barrier methods of contraception, from the time of the signing of informed consent through the last dose of study drug and for 30 days after dosing stops (1 ovulatory cycle), or agree to completely abstain from intercourse. Men with women partners of childbearing potential are also expected to practice effective barrier methods of contraception from the time of signing informed consent through the last dose of study drug and for 30 days after dosing stops. 7. Self-reported bedtime was between 9 pm and midnight on 4-7 nights per week. Exclusion Criteria: Participants must not meet any of the following exclusion criteria: 1. Body mass index > 32 as calculated from the participant's height (m) and weight (kg); weight (kg)/square height (m²) 2. Presence of a sleep disorder, such as a diagnosis of insomnia, narcolepsy, sleep paralysis, active somnambulism (history of childhood somnambulism is accepted), hypnagogic/ hypnopompic hallucinations, and REM behavior disorder, will be excluded based on the clinical interview. For sleep apnea syndrome, an apnea-hypopnea index > 15 per hour of sleep on the first screening night will be used as an exclusion criterion. For periodic limb movement disorder, an index of periodic limb movements during sleep associated with an arousal > 15 per hour of sleep on the first screening night will be used as an exclusion criterion. 3. History of epilepsy 4. Any previous serious head injury or stroke 5. Any evidence of psychiatric disorder (including Beck Depression Inventory [BDI] = 20 at screening, or a score of 3 on item related to suicidal ideas) 6. Evidence of any clinically significant, or unstable, acute or chronically progressive medical or surgical disorder (including planned medical procedures that may impact sleep), or any condition that may interfere with the absorption, metabolism, distribution, or excretion of the study drug, or may affect the participant's safety 7. Clinically significant and abnormal electrocardiogram (ECG; including QTc = 450 ms for males, 460 ms for females) or a history of cardiovascular disease including poorly controlled hypertension, ischemic heart disease, arrhythmia, or severe heart failure 8. Severe hepatic impairment 9. Positive qualitative urine drug screen (opiates, cocaine, amphetamine, cannabinoids, barbiturates, phencyclidine, benzodiazepines, methadone, propoxyphene) and alcohol test (breathalyzer), at screening and before each experimental visit 10. Current use of medications that are moderate or strong CYP3A4 inhibitors or inducers or CYP2B6 substrates (Appendix 1) 11. Use of any substance with psychotropic effects or properties known to affect sleep/wake, including hypnotics, neuroleptics, opioid derivatives, antihistamines, stimulants, antidepressants, within one week or five half-lives (whichever is longer) prior to PSG screening 12. Use of any over-the-counter sleep medications including tryptophan, valerian root (Valeriana officinalis), kava (Piper methysticum Forst), melatonin, St John's Wort (Hypericum perforatum), Alluna (herbal sleep supplement with valerian root), and hemp within one week or five half-lives (whichever is longer) prior to screening 13. Consumption of xanthine-containing beverages (i.e., tea, coffee, or cola) of more than 5 cups or glasses per day 14. Participation in any other trial within 30 days before the screening visit 15. Any travel across more than one time zone in the month prior to screening at any time during the study 16. Other exclusion criteria based on adverse events (AE) or serious adverse events (SAE) reported in the Investigator Brochure 17. Women who are pregnant, during the study or within one month after the study, or are breastfeeding 18. Individuals may be excluded from participating in the study based on the clinician's judgement. 19. Participants with lactose or galactose intolerance (galactosemia or glucose-galactose malabsorption)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lemborexant 5 MG [Dayvigo]
Lemborexant 5 mg will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.
Other:
Matching Placebo
Matching placebo will be taken orally once per day just prior to initiating laboratory-supervised daytime sleep episodes, for three consecutive days, within a few minutes before going to bed, with at least seven hours remaining before the planned time of awakening.

Locations

Country Name City State
Canada CIUSSS du Nord de l'ile de Montreal (CIUSSS-NIM) - Hôpital du Sacré-Cœur de Montréal (HSCM) Montréal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total sleep duration (objective measure) Assess the efficacy of lemborexant compared to placebo on PSG measured total sleep time (TST) during daytime recovery sleep using the mean data of the second and third daytime sleep episodes in each condition. during the intervention
Primary Wake after sleep onset (objective measure) Assess the efficacy of lemborexant compared to placebo on polysomnographically (PSG) measured wake after sleep onset (WASO) during daytime recovery sleep using the mean data of the second and third daytime sleep episodes in each condition during the intervention
Secondary Total sleep duration (subjective measure) Evaluate the participant-reported daytime recovery sleep quality, measured as subjective TST (sTST), under lemborexant in comparison to placebo using the mean data of the second and third daytime sleep episodes in each condition during the intervention
Secondary Wake after sleep onset (subjective measure) Evaluate the participant-reported daytime recovery sleep quality, measured as subjective WASO (sWASO), under lemborexant in comparison to placebo using the mean data of the second and third daytime sleep episodes in each condition. during the intervention
See also
  Status Clinical Trial Phase
Completed NCT01672502 - Fire Fighter Fatigue Management Program: Operation Fight Fatigue N/A
Completed NCT02978053 - Light Treatment to Shift-working Nurses N/A
Completed NCT00786357 - Sleep Enhancement Training Study for Experienced Shiftworkers Phase 1
Completed NCT00786266 - Sleep Enhancement Training Study for Novice Shiftworkers Phase 1
Completed NCT00900159 - Effects of Daytime Eszopiclone Administration in Shift Workers N/A
Completed NCT01988129 - Fire Fighter Fatigue Management Program: Operation Healthy Sleep N/A
Terminated NCT03879044 - Transcranial Direct Current Stimulation Therapy for Sleepiness Related to Shift Work Disorder (tDCS-SWORD) N/A
Completed NCT02541747 - Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors Phase 4
Completed NCT03153917 - Biological Rhythms Impact of 12 Hours Shift Work N/A
Recruiting NCT03956745 - Biomarkers for Circadian Timing in Healthy Adults
Active, not recruiting NCT03980340 - Breath Biomarkers for Sleep Loss and Circadian Timing
Completed NCT02901860 - Shift Work and Risk of Cardio-vascular Disease
Completed NCT00078312 - Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder Phase 3
Recruiting NCT04693182 - Health Promoting Work Schedules: The Effect of Abolishing Quick Returns N/A
Not yet recruiting NCT03087435 - Well-Being in Medical Residents in the HIBA
Terminated NCT01264913 - Cardiometabolic Risk of Shiftwork N/A
Completed NCT03813654 - Sleep and Circadian Treatments for Shift Workers N/A